Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI
Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI
Shots:
- The P-I study involves assessing the safety and PK of AT-527 (550 mg, q2, BID) vs PBO for 5 days in 20 healthy volunteers in a ratio (1:1) to treat COVID-19
- The result showed rapid attainment of steady state levels within 2days of dosing, predicted lung AT-9010 levels were consistently above the EC90 level of 0.5 µM for in vitro inhibition
- AT-527 is an orally administered, direct-acting antiviral agent, currently being evaluated in a P-II study for hospitalized patients with moderate COVID-19 and P-II virology study in patients with mild or mod. COVID-19 in an outpatient setting
Click here to read full press release/ article | Ref: Atea Pharma | Image: Atea Pharma
